Bhalla Narinder Pal 4

What Happened Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics (LXEO), was granted an award of 55,000 shares (no cash paid) and on 2026-07-01 sold 22,306 shares in an open-market transaction. The sale generated approximately $98,593 (weighted average price $4.42). The filing indicates the sale was executed to cover tax obligations related to the release of performance RSUs.

Key Details

• Transactions: 2026-06-29 — Award/acquisition of 55,000 shares @ $0.00; 2026-07-01 — Sale of 22,306 shares @ weighted avg $4.42 for $98,593.
• Sale price range: executed in multiple trades at prices between $4.341 and $4.73 (weighted average reported).
• Award composition: the 55,000-share award includes 49,500 RSUs; each RSU is a contingent right to receive one common share.
• Reason for sale: footnote confirms sale was to cover tax withholding on RSU release.
• Shares owned after transaction: not reported in this Form 4.
• Filing timeliness: filing date 2026-07-01; no indication in the filing that this was late.

Context

• RSUs are awards that vest or settle under specified conditions; the award itself is not an open-market purchase and carries future vesting/contingency implications.
• Sales to cover taxes are routine and do not necessarily signal a change in insider sentiment; purchases are generally more informative about bullish convictions.